Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ

Stock Track

Feb 24, 2025

Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.

The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.

Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1117228916"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117228916\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117228916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117228916","market":"us","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ","media":"Stock Track","content":"<p>Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.</p>\n\n<p>The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.</p>\n\n<p>Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Plunges 6.56% in Pre-Market on Licensing Deal with PATHOMIQ\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-24 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.</p>\n\n<p>The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.</p>\n\n<p>Myriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"","article_id":"1117228916","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117228916","pubTimestamp":1740404546,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Myriad Genetics  shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.The deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"Myriad Genetics因与PATHOMIQ达成许可协议而盘前暴跌6.56%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (NASDAQ: MYGN) shares plunged 6.56% in pre-market trading on Monday after announcing a strategic collaboration with PATHOMIQ to exclusively license their AI technology platform for prostate cancer testing in the US.\nThe deal will allow Myriad to provide urologists and radiation oncologists with AI-powered testing solutions alongside its existing molecular diagnostic tests for prostate cancer. While touted as expanding Myriad's oncology portfolio, investors appear concerned about the potential costs and impact on near-term financials.\nMyriad's President and CEO, Paul J. Diaz, highlighted the collaboration as accelerating innovation by leveraging PATHOMIQ's AI technology with Myriad's clinical expertise and commercial capabilities. The company plans to launch its first AI-driven prostate cancer test later this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}